3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
NETWORK
1
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
32
Thoracic
9
Gastrointestinal
9
Tumor-Agnostic
6
Other solid neoplasm
4
Gynecologic
3
Head & Neck
2
Dermatologic
2
Sarcoma
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
CNS
1
Breast
1
Conditions
Lymphoma, Mantle-Cell
1
Carcinoma
1
Interventions
Rituximab
376
Cyclophosphamide
179
Bendamustine Hydrochloride
109
obinutuzumab
100
Vincristine
94
fludarabine
92
ibrutinib
89
Prednisone
89
Doxorubicin
89
venetoclax
86
Lenalidomide
82
Gemcitabine
65
acalabrutinib
48
Brentuximab Vedotin
44
pembrolizumab
43
zanubrutinib
41
Dexamethasone
41
idelalisib
37
ofatumumab
32
Oxaliplatin
30
Chlorambucil
29
polatuzumab vedotin
25
blinatumomab
25
tocilizumab
24
Azacitidine
24
tositumomab I-131
22
Prednisolone
22
tisagenlecleucel
21
glofitamab
21
Nivolumab
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Axitinib
×
Lymphoid
×
Clear all
NCT00700258
2024-09-23
STAR-TOR
Pfizer
Completed
1,520 enrolled
24 charts